Alerts will be sent to your verified email
Verify Email
AUROPHARMA
Insufficient data
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Aurobindo Pharma is a leading API manufacturing company with a strong presence in various therapeutic domains. Its advanced R&D infrastructure supports the development and delivery of new products, ensuring profitability and growth.
Aurobindo Pharma major competitors are Alkem Laboratories, Glenmark Pharma, Abbott India, Glaxosmithkline Phar, Ipca Laboratories, Lupin, Ajanta Pharma.
Market Cap of Aurobindo Pharma is ₹59,689 Crs.
While the median market cap of its peers are ₹54,414 Crs.
Aurobindo Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Aurobindo Pharma is 4.45 and is ranked 8 out of its 8 competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | May Aug | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Sep Dec | Mar Jun Sep | Mar Jun Sep Dec | Mar Jun Dec | Mar Sep Dec | Mar Jun Sep Dec | Jun Sep Dec | Mar Jun Sep Dec | Jun Sep | Sep Dec | |||
| Investor Presentation | May Aug | Mar Jun Sep Dec | Mar Jun Sep Dec | Feb Mar May Jun Aug Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar | Jun Dec | Dec | Dec | |||
| Conference Call | Mar Jun | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Sep Dec | Mar | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Dec | |||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
